Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.37 |
| ▸ | BMP1 | P13497 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651838 | 0.88 | CXCR4 (0.43) | CXCR4TGM2CNR2 | |
| SCHEMBL6657761 | 0.87 | CXCR4 (0.43) | CXCR4TGM2CNR2 | |
| SCHEMBL6018231 | 0.85 | FOLH1 (0.41) | TGM2FOLH1 | |
| SCHEMBL6654733 | 0.84 | MEN1 (0.41) | CXCR4MEN1KMT2ATGM2BMP1 | |
| SCHEMBL6652095 | 0.82 | CXCR4 (0.60) | CXCR4MEN1KMT2ATGM2BMP1 | |
| SCHEMBL6694422 | 0.80 | FOLH1 (0.47) | TGM2FOLH1CNR2 | |
| SCHEMBL6018396 | 0.79 | TGM2 (0.37) | CXCR4KMT2ATGM2FOLH1 | |
| SCHEMBL6652792 | 0.78 | CXCR4 (0.58) | CXCR4MEN1KMT2ATGM2BMP1 | |
| SCHEMBL6658361 | 0.78 | CXCR4 (0.40) | CXCR4CNR2 | |
| SCHEMBL6655038 | 0.76 | CXCR4 (0.54) | CXCR4MEN1KMT2ATGM2BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1431290-A1 | NOVEL NITROGENOUS COMPOUND AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431290-A1 | NOVEL NITROGENOUS COMPOUND AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | NGLY1, NOD1, CCR1 | CXCR4 88/4885MEN1 575/4885KMT2A 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.